Xiaoman Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoman Song has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hongchao Ma
Department of Physiology, Shenzhen University Medical School, Shenzhen, China
60 shared publications - Liang Shi
Department of Physiology, Shenzhen University Medical School, Shenzhen, China
60 shared publications - Maolin Wang
Department of Physiology, Shenzhen University Medical School, Shenzhen, China
60 shared publications - Meiqi Li
Department of Physiology, Shenzhen University Medical School, Shenzhen, China
60 shared publications - Min Jia
Department of Physiology, Shenzhen University Medical School, Shenzhen, China
60 shared publications - Tobias Achu Muluh
Shenzhen University Medical School, Shenzhen University, Shenzhen, China
60 shared publications
Latest Publications
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Target sequences of shRNAs and sgRNAs used in this study.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Target sequences of shRNAs and sgRNAs used in this study.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Antibodies used in this study.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Antibodies used in this study.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Antibodies used in this study.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression
Antibodies used in this study.